Shilpa Medicare is engaged in the business of high quality Active Pharmaceuticals Ingredients (APIs), Intermediates, Formulations, New Drug delivery system, Peptides, Biotech products, and Specialty chemicals using sophisticated technology. SML is one of the worlds leading suppliers of Oncology/ Non Oncology API’s and intermediates.
Financial Results:
Shilpa Medicare Ltd reported Revenues for Q2FY24 of ₹312.98 Crores up from ₹262.91 Crore year on year, a rise of 19.04%.
Total Expenses for Q2FY24 of ₹305.62 Crores up from ₹289.69 Crores year on year, a rise of 5.5%.
Consolidated Net Profit of ₹1.57 Crores from -₹18.58 Crores in the same quarter of the previous year.
The Earnings per Share is ₹0.19, from -₹2.15 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.